Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February—Caris Life Sciences presented a study at the December 2013 CTCR-AACR San Antonio Breast Cancer Symposium on identifying potentially actionable therapeutic targets and clinical strategies for triple-negative breast cancer (TNBC). The biomarker data used for the study were obtained using the company’s tumor profiling service, Caris Molecular Intelligence.
February 2014—Leica Biosystems announced a partnership with EyesFinder, a developer of visual search technology, to create decision support tools for pathologists.
February 2014—Nanosphere received FDA clearance for its Verigene Gram-Negative Blood Culture (BC-GN) Test, an in vitro diagnostic test that determines resistance to commonly used antibiotics up to two to three days faster than conventional identification methods. Among the critical genetic markers of antibiotic resistance identified by Verigene BC-GN are five genes that can identify carbapenem-resistant Enterobacteriaceae.
February 2014—Life Technologies released general-purpose reagents (GPRs) for the development of molecular diagnostic assays based on qPCR and capillary electrophoresis (CE). GPR products are for laboratory use and come with a higher quality assurance than research-use-only products. For CE (for sequencing and fragment analysis), BigDye Terminator Cycle Sequencing Reagents provide the required components for cycle sequencing reactions in a premixed format. They are optimized for longer, higher-quality reads with uniform peak heights and optimal signal balance and are appropriate for a range of applications, including de novo sequencing and resequencing.
February—NanoString Technologies announced the availability of the Prosigna Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of this year.
February 2014—Myriad Genetics presented clinical data from a research study showing that its HRD (homologous recombination deficiency) test predicted platinum response in patients with triple-negative breast cancer (P=0.0003). The HRD score predicted, with a sensitivity of 100 percent, all of the patients who experienced a complete response after presurgical treatment with platinum. In addition, the results showed that the HRD score was generalizable across all breast cancer subtypes.
January 2014—Air Science introduced its new Purair Eco line of energy-saving ductless fume hoods designed for chemical and particulate protection over a broad range of laboratory and industrial applications.
January 2014—Mettler Toledo has embedded radio- frequency identification tags in all of its premium Rainin air displacement pipettes, including its recently released E4 XLS electronic model. RFID tagging helps labs establish advanced calibration schedules through heightened pipette tracking.
January 2014—Spring Bioscience has added the Anti-PTEN (SP218) rabbit monoclonal immunohistochemistry antibody to its portfolio of antibodies for cancer research.
January 2014—Transgenomic in October announced the results of a research collaboration with MD Anderson Cancer Center employing the company’s ICE COLD-PCR platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free DNA present in the blood as were originally found in primary tumors. In a subset of patients followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.
